Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Cancer stem cells (CSCs) have important roles in tumour development, relapse and
metastasis; the intrinsic self-renewal characteristics and tumorigenic properties of these cells …

Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Cancer immunoediting is a hallmark of cancer that predicts that lymphocytes kill more
immunogenic cancer cells to cause less immunogenic clones to dominate a population …

Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor
microenvironment that renders it largely refractory to immunotherapy. We implemented a …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer
featured with high intra-tumoral heterogeneity and poor prognosis. To comprehensively …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

The most prominent homozygous deletions in cancer affect chromosome 9p21. 3 and
eliminate CDKN2A/B tumor suppressors, disabling a cell-intrinsic barrier to tumorigenesis …

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often
ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated …